A Randomized, Multicenter, Open-label, Phase III Trial comparing Trastuzumab plus Pertuzumab plus a Taxane following Anthracyclines versus Trastuzumab Emtansine plus Pertuzumab following Anthracyclines as Adjuvant Therapy in Patients with Operable HER 2 Positive Primary Breast Cancer

Trial Profile

A Randomized, Multicenter, Open-label, Phase III Trial comparing Trastuzumab plus Pertuzumab plus a Taxane following Anthracyclines versus Trastuzumab Emtansine plus Pertuzumab following Anthracyclines as Adjuvant Therapy in Patients with Operable HER 2 Positive Primary Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2017

At a glance

  • Drugs Trastuzumab emtansine (Primary) ; Anthracyclines; Docetaxel; Paclitaxel; Pertuzumab; Trastuzumab
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KAITLIN
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 24 Feb 2017 Planned End Date changed from 1 May 2023 to 1 Jan 2024.
    • 24 Feb 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Jan 2024.
    • 19 Nov 2015 Planned number of patients changed from 2500 to 1846 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top